Concurrent EGFR‐TKI and Thoracic Radiotherapy as First‐Line Treatment for Stage IV Non‐Small Cell Lung Cancer Harboring EGFR Active Mutations

LESSONS LEARNED. This single‐arm, phase II study shows that concurrent EGFR‐tyrosine kinase inhibitor plus thoracic radiotherapy as the first‐line treatment for stage IV non‐small cell lung cancer harboring EGFR active mutations provides long‐term control for the primary lung lesion, and 1‐year prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, LinPeng, Wang, Yanmei, Xu, Zihan, Yang, Qiao, Zhu, Guangkuo, Liao, Xing‐Yun, Chen, Xiewan, Zhu, Bo, Duan, Yuzhong, Sun, Jianguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693693/
https://www.ncbi.nlm.nih.gov/pubmed/31040256
http://dx.doi.org/10.1634/theoncologist.2019-0285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693693/
https://www.ncbi.nlm.nih.gov/pubmed/31040256
http://dx.doi.org/10.1634/theoncologist.2019-0285

Ejemplares similares